AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A Study of MEDI-575 in Patients With Advanced Solid Malignancies
- First Posted Date
- 2010-04-13
- Last Posted Date
- 2013-02-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 22
- Registration Number
- NCT01102400
- Locations
- 🇯🇵
Research Site, Sunto-gun, Japan
Japanese Single and Multiple Ascending Dose (JSMAD), Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) Study of AZD5069
- First Posted Date
- 2010-04-08
- Last Posted Date
- 2015-06-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 63
- Registration Number
- NCT01100047
- Locations
- 🇬🇧
Research Site, Croydon, United Kingdom
A Single and Multiple Ascending Dose Study With AZD9164 Given for 13 Days in Healthy Male and Female Japanese Subjects
- First Posted Date
- 2010-03-31
- Last Posted Date
- 2010-12-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 27
- Registration Number
- NCT01096563
- Locations
- 🇬🇧
Research Site, Croydon, United Kingdom
Study To Assess the Pharmacokinetics of AZD1656 During Coadministration With Simvastatin
- First Posted Date
- 2010-03-31
- Last Posted Date
- 2010-11-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 44
- Registration Number
- NCT01096940
- Locations
- 🇺🇸
Research Site, San Antonio, Texas, United States
To Investigate the Relative Efficacy of Terbutaline Turbuhaler® and Salbutamol Pressurized Metered Dose Inhaler (pMDI) a Single Blind Study
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- Other: pMDI placebo pMDIOther: Placebo Turbuhaler®
- First Posted Date
- 2010-03-30
- Last Posted Date
- 2012-08-31
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 24
- Registration Number
- NCT01096017
- Locations
- 🇯🇵
Research Site, Tokyo, Japan
A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise
Phase 3
Completed
- Conditions
- Type 2 Diabetes
- Interventions
- First Posted Date
- 2010-03-30
- Last Posted Date
- 2017-02-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1179
- Registration Number
- NCT01095653
- Locations
- 🇨🇳
Local Institution, Yung Kang city, Taiwan
Investigate the Effect of AZD1656 on the Pharmacokinetics of Sitagliptin in Patients With Type 2 Diabetes Mellitus
- First Posted Date
- 2010-03-30
- Last Posted Date
- 2010-07-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 12
- Registration Number
- NCT01095991
- Locations
- 🇩🇪
Research Site, Neuss, Germany
Study to Evaluate Methods That Assess the Effect of AZD4017 in Adipose Tissue
- First Posted Date
- 2010-03-30
- Last Posted Date
- 2010-12-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 15
- Registration Number
- NCT01096004
- Locations
- 🇸🇪
Research Site, Goteborg, Sweden
A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone
Phase 3
Completed
- Conditions
- Type 2 Diabetes
- Interventions
- First Posted Date
- 2010-03-30
- Last Posted Date
- 2017-09-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1484
- Registration Number
- NCT01095666
- Locations
- 🇰🇷
Local Institution, Seoul, Korea, Republic of
A Study Assessing Inhibition of Serum Thromboxane B2 Levels With PN400 and Low Dose Aspirin
- First Posted Date
- 2010-03-29
- Last Posted Date
- 2010-12-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 40
- Registration Number
- NCT01094483
- Locations
- 🇺🇸
Research Site, Overland Park, Kansas, United States